Lipodystrophy in children and adolescents with acquired immunodeficiency syndrome and its relationship with the antiretroviral therapy employed

Jornal de Pediatria

Volumn 85, Issue 4, 2009, Pages 329-334

  Sarni, Roseli Oselka Saccardo ^a,b,d   De Souza, Fabíola Isabel Suano ^a,b   Battistini, Tânia Regina Beraldo ^a,b   Pitta, Tassiana Sacchi ^b   Fernandes, Ana Paula ^b   Tardini, Priscila Chemiotti ^b   Fonseca, Fernando Luis Affonso ^b,c   Dos Santos, Valter Pinho Dos ^a,b   Lopez, Fábio Ancona ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b FACULDADE DE MEDICINA DO ABC   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d FMABC ^*  (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; DIDANOSINE; EFAVIRENZ; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDINAVIR; INSULIN; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TRIACYLGLYCEROL; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ANTHROPOMETRIC PARAMETERS; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL EVALUATION; DISEASE ASSOCIATION; DYSLIPIDEMIA; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID BLOOD LEVEL; LIPODYSTROPHY; MALE; PRESCHOOL CHILD; SCHOOL CHILD; TREATMENT DURATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; ANTHROPOMETRY; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHI-SQUARE DISTRIBUTION; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; DYSLIPIDEMIAS; FEMALE; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; LIPIDS; MALE;

EID: 68949105689     PISSN: 00217557     EISSN: None     Source Type: Journal    
DOI: 10.2223/JPED.1910     Document Type: Article

References (30)

1. Centers for Disease Control and Prevention. Guidelines for the use of antiretroviral agents in pediatric HIV infection. http://www. aidsinfo.nih.gov Access: 10/10/2008.
2. Jaquet D, Lèvine M, Ortega-Rodriguez E, Faye A, Polak M, Vilmer E, et al. Clinical and metabolic presentation of the lipodystrophic syndrome in HIV-infected children. AIDS. 2000;14:2123-2128 (Pubitemid 30792485)
3. Romanelli RM, Pinto JA, Melo LJ, Vasconcelos MA, Pereira Rde M. Effectiveness of dual and triple antiretroviral therapy in the treatment of HIV-infected children. J Pediatr (Rio J). 2006;82:260-265 (Pubitemid 44244591)
4. Noor MA, Seneviratne T, Aweeka FT, Lo JC, Schwarz JM, Mulligan K, et al. Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized placebo controlled study. AIDS. 2000;16:F1-8. (Pubitemid 34274457)
5. Barbaro G, Fisher SD, Lipshultz SE. Pathogenesis of HIV associated cardiovascular complications. Lancet Infect Dis. 2001;1:115-124 (Pubitemid 33586046)
6. Pinti M, Salomoni P, Cossarizza A. Anti-HIV drugs and the mitochondria. Biochem Biophys Acta. 2006;1757:700-707
7. Tang AM, Lanzilotti J, Hendricks K, Gerrior J, Ghosh M, Woods M, et al. Micronutrients: current issues for HIV care providers. AIDS. 2005;19:847-861 (Pubitemid 40834927)
8. Mc Crindle BW, Urbina EM, Dennison BA, Jacobson MS, Steinberger J, Rocchini AP, et al. Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing. Circulation. 2007;115:1948-1967 (Pubitemid 46598908)
9. Alves C, Oliveira AC, Brites C. Lipodystrophic syndrome in children and adolescents infected with the human immunodeficiency virus. Bras J Infect Dis. 2008;12:342-348
10. Centers for Disease Control and Prevention. 1994 Revised classification system for human immunodeficiency virus infection less than 13 years age. MMWR. 1994;43:1-10.
11. Associação Brasileira de Empresas de Pesquisa - 2003. http:// www.abep.org/codigosguias/Criterio-Brasil-2008.pdf. Access: 07/07/2009.
12. Monteiro CA, Nazario CL. Evolução de condicionantes ambientais da saúde na infância na cidade de São Paulo (1984-1996). Rev Saude Publica. 2000;34:13-18
13. World Health Organization: Physical Status. The use and interpretation of anthropometry. WHO Technical Report Series 854. Geneva: WHO; 1995.
14. Kuczmarski RJ, Ogden CL, Grummer-Strawn. CDC growth charts: United States. Advance data from vital and health statistics; n°. 314. Hyattsville, MD: NCHS; 2000.
15. Marshall WA, Tanner JM. Growth and physiological development during adolescence. Annu Rev Med. 1975;19:283-300.
16. Valente AM, Reis AF, Machado DM, Succi RC, Chacra R. Alteraç ões metabólicas da síndrome lipodistrófica do HIV. Arq Bras Endocrinol Metab. 2005;49:871-881
17. National Cholesterol Education Program (NCEP): highlights of the report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. Pediatrics. 1992;89:495-501.
18. Tresaco B, Bueno G, Pineda I, Moreno LA, Garagorri JM, Bueno M. Homeostatic model assessment (HOMA-IR) index cut-off values to identify the metabolic syndrome in children. J Physiol Biochem. 2005; 61:381-388 (Pubitemid 41269262)
19. SPSS. SPSS Base 13.0: Base Users Guide. Chicago, 2004.
20. Dean AG. Epi Info™ and Epi Map: Current status and plans for Epi Info™ 2000. J Pub Health Manag Pract. 1999;5:54-57
21. Amaya RA, Kozinetz CA, McMeans A, Schwarzwald H, Kline MW. Lipodistrophy syndrome in human immunodeficiency virus-infected children. Pediatr Infect Dis J. 2002;21:405-410 (Pubitemid 34532934)
22. Santos FS, Rangel LG, Saucedo GP, Rosales GV, Novales MG. Hypertriglyceridemia and hypercholesterolemia in human immunodeficiency vírus-1 infected children treated with protease inhibitors. Arch Med Res. 2006;37:129-132 (Pubitemid 41727902)
23. Brett-Major DM, Ganesan A. Dyslipidemia management in patients with human immunodeficiency vírus. Infect Dis Clin Pract. 2007;15:7-16. (Pubitemid 46116457)
24. Carr A, Samaras K, Thorisdottir A. Diagnosis, pediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet. 1999;353:2093-2099 (Pubitemid 29278477)
25. Young J, Weber R, Rickenbach M, Furrer H, Bernasconi E, Hirschel B, et al. Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study. Antivir Ther. 2005;10:585-591 (Pubitemid 41224950)
26. DAD Study Group, Friis-Møller N, Reiss P, Sabin CA, Weber R, Monforte A, et al. Class of antiretroviral drugs and the risk of myocardial infarction. DAD Study Group. N Engl J Med. 2007;356:1723-1735
27. Carr A, Miller J, Law M, Cooper DA. A syndrome of lipoatrophy, lactic acidemia and liver dysfunction associated with HIVnucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS. 2000;14:F25-32. (Pubitemid 30132938)
28. Mallon PW, Miller J, Cooper DA, Carr A. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1 infected men starting therapy. AIDS. 2003;17:971-979 (Pubitemid 36549708)
29. a ed. Brasília: Ministério da Saúde; 2006.
30. May M, Sterne JA, Sabin C, Costagliola D, Justice AC, Thiébaut R, et al; Antiretroviral Therapy (ART) Cohort Collaboration. Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS. 2007;21:1185-1197